Skip to main content
Psychopharmacology Bulletin All Volumes & Issues VOL 37 Supplement No. 1 Advances in Recognition...

Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective

Psychopharmacology Bulletin 37(Suppl. 1) :97-107 , 2003/04/22

Abstract

Social anxiety disorder frequently begins in early life and is associated with the subsequent development of comorbid conditions such as depressive and substance use disorders. Social anxiety disorder, particularly the generalized subtype, is characterized by marked impairment in numerous functional domains, including education and social relations. Paroxetine, the first medication to receive an indication in the United States for the treatment of social anxiety disorder, has been shown to be effective in 50% to 60% of patients. The mechanism of action of paroxetine in the treatment of social anxiety disorder is at present unclear. A possible role for early treatment to prevent complications of social anxiety disorder should be explored.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Murray B. Stein, MD, FRCPC. Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective. Psychopharmacology Bulletin. 2003/04/22; 37(Suppl. 1):97-107.